Literature DB >> 17845912

DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.

Mahmoud Al-Khrasani1, Mariana Spetea, Tamas Friedmann, Pal Riba, Kornel Király, Helmut Schmidhammer, Susanna Furst.   

Abstract

Peripheral micro-opioid receptors (MOR) have emerged as important components of inhibitory nociceptive pathways. Here, the antinociceptive effects of MOR agonists, the 6beta-glycine derivative of 14-O-methyloxymorphone (HS-731), DAMGO and morphine were evaluated in a mouse model of visceral pain. The abdominal acetic acid-induced writhing test was used to examine the peripheral, preemptive antinociceptive opioid action on visceral nociception. HS-731 administered subcutaneously (s.c.) or intracerebroventricularly (i.c.v.) dose-dependently and completely inhibited writhing, being 24-598-fold more potent, depending on the administration route, than two selective MOR agonists, the enkephalin analogue [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]enkephalin (DAMGO) and morphine. A longer duration of action (2-3 h) was induced by HS-731 given before acetic acid, while shorter effect was produced by morphine (30-60 min) and DAMGO (30-45 min). The antinociceptive effects of systemic opioids were reversed by the s.c. opioid antagonist, naloxone. Blocking of central MOR by the selective MOR antagonist D-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH(2) (CTAP, i.c.v.) resulted in a significant reduction of antinociception of s.c. morphine, whereas it completely failed to antagonize the effects of systemic HS-731 or DAMGO. In in vitro studies, HS-731 and DAMGO, but not morphine showed high intrinsic efficacy, naltrexone-sensitive agonist effect at MOR of the rat vas deferens. These data demonstrate that selective activation of peripheral MOR by systemic s.c. HS-731 or DAMGO produces potent peripheral, preemptive visceral antinociception, while morphine's effects are mediated primarily through central mechanisms. Our findings support the role of peripheral MOR in the pathology of pain states involving sensitization of peripheral nociceptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845912     DOI: 10.1016/j.brainresbull.2007.07.008

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  11 in total

1.  In vivo Functional Evaluation of Increased Brain Delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes.

Authors:  Annika Lindqvist; Jaap Rip; Joan van Kregten; Pieter J Gaillard; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2015-08-15       Impact factor: 4.200

2.  Protective role of μ opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice.

Authors:  Francesca Saccani; Laura Anselmi; Ingrid Jaramillo; Simona Bertoni; Elisabetta Barocelli; Catia Sternini
Journal:  J Neurosci Res       Date:  2012-07-17       Impact factor: 4.164

3.  Activation of μ opioid receptors modulates inflammation in acute experimental colitis.

Authors:  L Anselmi; J Huynh; C Duraffourd; I Jaramillo; G Vegezzi; F Saccani; E Boschetti; N C Brecha; R De Giorgio; C Sternini
Journal:  Neurogastroenterol Motil       Date:  2015-02-17       Impact factor: 3.598

4.  Opioid receptor characterisation of neuronally stimulated isolated human vas deferens.

Authors:  James Root; Ana Monica Lopes Correia Wakenhut; Holly Siggins; Sidath Katugampola; Carolyn Napier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06-15       Impact factor: 3.000

5.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

6.  Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Authors:  Mariana Spetea; Petra Windisch; Yan Guo; Indre Bileviciute-Ljungar; Johannes Schütz; Muhammad Faheem Asim; Ilona P Berzetei-Gurske; Pal Riba; Kornel Kiraly; Susanna Fürst; Mahmoud Al-Khrasani; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2011-01-14       Impact factor: 7.446

7.  Synthesis, Biological, and Structural Explorations of New Zwitterionic Derivatives of 14- O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives.

Authors:  Mariana Spetea; Silvia B Rief; Tanila Ben Haddou; Monika Fink; Elka Kristeva; Harald Mittendorfer; Stefanie Haas; Nora Hummer; Valeria Follia; Elena Guerrieri; Muhammad Faheem Asim; Sonja Sturm; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2019-01-03       Impact factor: 7.446

8.  Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.

Authors:  Tanila Ben Haddou; Davide Malfacini; Girolamo Calo; Mario D Aceto; Louis S Harris; John R Traynor; Andrew Coop; Helmut Schmidhammer; Mariana Spetea
Journal:  Mol Pain       Date:  2014-07-24       Impact factor: 3.395

Review 9.  On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance.

Authors:  Susanna Fürst; Zoltán S Zádori; Ferenc Zádor; Kornél Király; Mihály Balogh; Szilvia B László; Barbara Hutka; Amir Mohammadzadeh; Chiara Calabrese; Anna Rita Galambos; Pál Riba; Patrizia Romualdi; Sándor Benyhe; Júlia Timár; Helmut Schmidhammer; Mariana Spetea; Mahmoud Al-Khrasani
Journal:  Molecules       Date:  2020-05-26       Impact factor: 4.411

10.  Comparisons of In Vivo and In Vitro Opioid Effects of Newly Synthesized 14-Methoxycodeine-6-O-sulfate and Codeine-6-O-sulfate.

Authors:  Ferenc Zádor; Amir Mohammadzadeh; Mihály Balogh; Zoltán S Zádori; Kornél Király; Szilvia Barsi; Anna Rita Galambos; Szilvia B László; Barbara Hutka; András Váradi; Sándor Hosztafi; Pál Riba; Sándor Benyhe; Susanna Fürst; Mahmoud Al-Khrasani
Journal:  Molecules       Date:  2020-03-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.